EARLY-STAGE bladder cancer can be effectively diagnosed using unprocessed urine samples at the point of care, achieving 90% ...

A new report dives into the evolving clinical trial landscape and transformative therapies changing lives for bladder cancer ...

· Tempus AI, Inc. (NASDAQ: TEM) started 2025 announcing the National Launch of its FDA -approved xT CDx Test, a 648-gene next-generation sequencing test for solid tumor profiling, which includes ...

Bladder cancer has a cure rate of over 90% when detected early, but it has a high recurrence rate of 70%, necessitating ...

The bladder cancer test developer says it will go to court if an unfavourable US reimbursement decision is not reversed.

Bladder cancer is one of the most common malignant tumors in urinary system, and the treatment faces huge challenges.

A combination therapy of two drugs — a statin and a protein inhibitor — may help suppress the creation and growth of tumors ...

Key Takeaways JNJ will buy Intra-Cellular Therapies, producer of a drug for bipolar disorder, for $14.6 billion. Eli Lilly ...

Pfizer Inc. has announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.

Pfizer CEO Albert Bourla said he had spoken to Robert F. Kennedy Jr. in an effort to “find opportunities on things we can ...